Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice

Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice

Fibroblast growth factor 21 (FGF21) is a promising therapeutic agent for treatment of type 2 diabetes (T2D) and non-alcoholic steatohepatitis (NASH). We show that therapeutic levels of FGF21 were achieved following subcutaneous (s.c.) administration of mRNA encoding human FGF21 proteins. The efficac...

Full description

Bibliographic Details
Main Authors: Stefano Bartesaghi, Kristina Wallenius, Daniel Hovdal, Mathias Liljeblad, Simonetta Wallin, Niek Dekker, Louise Barlind, Nigel Davies, Frank Seeliger, Maria Sörhede Winzell, Sima Patel, Matt Theisen, Luis Brito, Nils Bergenhem, Shalini Andersson, Xiao-Rong Peng
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
mRNA therapy
LNP
FGF21
insulin resistance
steatosis
DIO mice
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253122000865

Internet

http://www.sciencedirect.com/science/article/pii/S2162253122000865

Similar Items